Changes in Hong Kong stocks | Boan Biotech (06955) rose more than 4% in the afternoon BA2201 approved for clinical use in China to treat inflammatory bowel disease

The Zhitong Finance App learned that Boan Biotech (06955) rose more than 4% in the afternoon. As of press release, it had risen 4.33% to HK$3.01, with a turnover of HK$1,167,800.

According to the news, Boan Biotech announced in the afternoon that BA2201, a Class 1 innovative drug independently developed by the company, has been approved by the Drug Evaluation Center of the China National Drug Administration to carry out clinical trials. The drug under development is a long-acting bispecific antibody targeting TL1A and IL-23 (p19), and is intended to treat autoimmune diseases such as inflammatory bowel disease.

The company said that as BA2201 enters the clinical stage, the company will accelerate follow-up research and speed up the verification of this treatment plan that takes into account dual-target intervention and the convenience of long-term administration. In addition to BA2201, the company also lays out various dual-antibody and multi-antibody drug candidates around the field of autoimmune disease treatment. The company will steadily advance the development and clinical transformation of related projects to provide patients with more innovative treatment options in the field of this disease.